

Box S1: Variable descriptions

Variables	Descriptions
Patient demographics	
Age at diagnosis	Defined at time of filling in questionnaire shortly after diagnosis
Educational level at diagnosis	Defined as low: primary or secondary education or less, medium: vocational education, and high: university or higher education.
Parity at diagnosis	Yes / no
Smoking status at diagnosis	Classified as never smoker, former smoker, and current smoker
Family history of cancer	Yes / no
Frailty at diagnosis	Evaluated by Groningen Frailty Index (GFI). Defined as < 4: non-frail, > 4: frail.
Clinical data	
Histology at diagnosis	Classified as high-grade serous, low-grade serous, mucinous, endometrioid, clear cell, carcinosarcoma, adenocarcinoma NOS
FIGO stage at diagnosis	Classified as I, II, III, IV.
Performance status at diagnosis	Evaluated according to WHO/ECOG criteria. Defined as 0: fully active, 1: restricted in physical strenuous activity, 2: ambulatory and capable of selfcare but unable to carry out any other work activities, in bed <50% of waking hours, 3: capable of only limited selfcare, in bed >50% of waking hours, 4: completely disabled, totally confined to bed or chair, 5: dead.
BRCA1/2 tests	
Tumor test performed	Yes / no
Germline test performed	Yes / no
Date of tumor / germline test	Day / month / year
Tumor test result	Classified as: no tumor pathogenic variant, tumor pathogenic variant in <i>BRCA1</i> or tumor pathogenic variant in <i>BRCA2</i>
Germline test result	Classified as: no germline pathogenic variant, germline pathogenic variant in <i>BRCA1</i> or germline pathogenic variant in <i>BRCA2</i>

Table S1: Known *BRCA1/2* germline pathogenic variant status by time since diagnosis

Tested: known <i>BRCA1/2</i> GPV status	All EOC patients <i>n</i> =250		
	<i>n</i>	%	Cum. %
Within 1 year	159	63.6	63.6
After 1 to 1.5 years	24	9.6	73.2
After 1.5 to 2 years	8	3.2	76.4
After 2 to 2.5 years	4	1.6	78.0
After 2.5 to 3 years	2	0.8	78.8
After 3 to 5 years	4	1.6	80.4
N/A, unknown <i>BRCA1/2</i> GPV status	49	19.6	100.0

Abbreviations: Cum, cumulative; GPV, germline pathogenic variant.

Table S2: *BRCA1/2* pathogenic variants by histological subtype (HGSC versus non-HGSC) for all tested patients and by period of diagnosis (period I and period II)

	All tested patients <i>n</i> =201		Tested patients diagnosed in period I ^a <i>n</i> =137		Tested patients diagnosed in period II ^a <i>n</i> =64	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
<i>BRCA1/2</i> GPV	15	7.5	11	8.0	4	6.3
<i>HGSC</i>	15	100.0	11	100.0	4	100.0
<i>Non-HGSC</i>	-	-	-	-	-	-
Somatic <i>BRCA1/2</i> PV	9	4.5	4	2.9	5	7.8
<i>HGSC</i>	9	100.0	4	100.0	5	100.0
<i>Non-HGSC</i>	-	-	-	-	-	-

Abbreviations: GPV, germline pathogenic variant; HGSC, high-grade serous carcinoma; PV, pathogenic variant. ^a Period I: January 1, 2016, until July 1, 2018. Period II: July 1, 2018, until January 1, 2020.

Table S3: Potential predictors of receiving *BRCA1/2* testing (multivariable logistic regression)

Variables	OR (95% CI)	P value
Age at diagnosis	0.96 (0.93-0.99)	0.012
Histology at diagnosis		
HGSC (ref.)	1.00	-
Non-HGSC	0.23 (0.11-0.46)	<0.001
Adenocarcinoma NOS	0.29 (0.04-1.89)	0.195
Period of diagnosis	1.11 (0.54-2.28)	0.777

Abbreviations: OR, odds ratio; CI, confidence interval; HGSC, high-grade serous carcinoma; ref, reference; NOS, not otherwise specified.